Evidence map›Paper›PMID 33616746›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2021

Human glutathione peroxidase codon 198 variant increases nasopharyngeal carcinoma risk and progression.

Ala Laribi, Sahar Aouf, Sallouha Gabbouj, Noureddine Bouaouinaa, Abdelfattah Zakhama, Hedi Harizi

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ala LaribiLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia.
Sahar AoufLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia.
Sallouha GabboujLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia.
Noureddine BouaouinaaLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia.
Abdelfattah ZakhamaLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia.
Hedi HariziLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia. hharizi@hotmail.fr.ORCID http://orcid.org/0000-0003-3856-3311
University of Monastir · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGlutathione peroxidase 1 (GPx-1) is a selenium-dependent detoxifying enzyme involved in the protection of cells against oxidative damage. Some genetic association studies reported significant associations between GPx-1 Pro198Leu variant and carcinogenesis across different populations; however, the impact of this variant on nasopharyngeal carcinoma (NPC) has not been explored. Therefore, the present study was planned to evaluate the potential involvement of the GPx-1 Pro198Leu variant and plasma GPx activity in the risk of developing NPC in a Tunisian population.

methodsThe GPx-1 Pro198Leu genotype was determined in 327 NPC patients and 150 healthy controls by the RFLP-PCR analysis. The correlation between the GPx-1 variant and the clinicopathological parameters was examined. GPx activity was assessed in the plasma of 119 NPC patients and 58 healthy control subjects and according to GPx-1 genotypes and clinicopathological characteristics of NPC patients.

resultsA significant association was found between GPx-1 Pro198Leu variant and NPC risk in a Tunisian population. The allelic frequencies of Pro and Leu alleles were 32% versus 68% and 41% versus 59% in NPC cases and controls, respectively. Thus, the minor 198 Leu allele increased significantly in NPC patients and appeared as a potential risk factor for NPC occurrence (OR = 1.48, CI 95% = 1.14-1.91, p = 0.002). The plasma GPx activity was significantly higher in NPC patients than in controls (p = 0.03). According to the clinicopathological characteristics of NPC patients, GPx activity decreased significantly in patients with lymph node metastasis (p = 0.004).

conclusionThis is the first study showing a strong association between GPx-1 Pro198Leu genetic variant and NPC risk. GPx-1 Pro198Leu variant increased the development of regional lymph node metastasis. Plasma GPx activity was higher in NPC patients. Thus, GPx-1 gene could be considered as a determinant factor influencing NPC risk and progression.

Indexed as

Nasopharyngeal NeoplasmsCase-Control StudiesCodonGenetic Predisposition to DiseaseGenotypeGlutathione PeroxidaseGlutathione Peroxidase GPX1HumansNasopharyngeal CarcinomaRisk FactorsCodonGlutathione PeroxidaseGlutathione Peroxidase GPX1GPX1 protein, human198Leu mutationClinicopathological parametersGpx-1 geneNasopharyngeal carcinomaPlasma GPx activity

Identifiers

PMID33616746
OpenAlexW3130194160

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.